TAM12112 S.L.C.

112TH CONGRESS 2D SESSION	S.
------------------------------	----

To permit manufacturers of generic drugs to provide additional warnings with respect to such drugs in the same manner that the Food and Drug Administration allows brand names to do so.

## IN THE SENATE OF THE UNITED STATES

Mr.	LEAHY introduced the following	bill;	which	was	${\rm read}$	twice	and	referi	ed
	to the Committee on								

## A BILL

To permit manufacturers of generic drugs to provide additional warnings with respect to such drugs in the same manner that the Food and Drug Administration allows brand names to do so.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "Patient Safety and
- 5 Generic Labeling Improvement Act".

TAM12112 S.L.C.

	$\angle$
1	SEC. 2. WARNING LABELING WITH RESPECT TO GENERIC
2	DRUGS.
3	Section 505(j) of the Federal Food, Drug, and Cos-
4	metic Act (21 U.S.C. 355(j)) is amended by adding at the
5	end the following:
6	"(11)(A) Notwithstanding any other provision
7	of this Act, the holder of an approved application
8	under this subsection may change the labeling of a
9	drug so approved in the same manner authorized by
10	regulation for the holder of an approved new drug
11	application under subsection (b).
12	"(B) In the event of a labeling change made
13	under subparagraph (A), the Secretary may order
14	conforming changes to the labeling of the equivalent
15	listed drug and each corresponding drug approved

listed drug and each corresponding drug approved

under this subsection.".

16